News

Pharma hub services are evolving as manufacturers navigate specialty therapy growth, digital transformation, vendor transitions, and new models for patient access and support.

In this week's Pharma Pulse, a senior source denies AstraZeneca and Bristol Myers Squibb are in merger talks, Cleveland Clinic and Arrive AI push drone delivery toward pharma's last mile, Kenco's AI rollout signals where 3PL is headed, and TailorMed and WeInfuse team up to expand infusion access.

Cleveland Clinic's new prescription drone delivery program and Arrive AI's planned collaboration with LifeSpan Pharmacy highlight growing interest in drone technology for last-mile logistics.

Kenco has put DeepFabric's AI agents into live production across its 3PL operations, with plans to scale to 20 agents within a year.

Serialization data does more than meet DSCSA rules. See how connected event histories improve recalls, returns and inventory visibility.

Nick Niemeyer of API Innovation Center on how the National Fragility Index could help reduce US drug shortage risk.

Four pharma experts discuss industry trends in M&A, direct-to-patient sales, patient access and commercial strategy at the H1 midyear mark.

The Section 232 tariff deadline for 17 major drugmakers has arrived. Here's what pharma supply chain teams need to know now.

Domestic manufacturing can reduce certain dependencies, but reliable pharmaceutical commercialization requires qualified redundancy, sustainable economics, quality maturity and decision-ready visibility across the full supply network.

In this week's Pharma Pulse, Infinitus launches an AI-first hub model, EVERSANA is tapped to commercialize Innovacell's regenerative cell therapy in the US, Peli BioThermal and PAXAFE pair packaging with predictive cold chain intelligence, and Ember LifeSciences strikes a distribution alliance with Japan's top pharma wholesaler.

Ember LifeSciences and Alfresa, Japan's top pharma wholesaler, form a cold chain alliance as biologics and specialty distribution demand grows.

Gifthealth's Chip Parkinson shares his outlook on direct-to-patient models in specialty, regulation and platform design heading into 2027.

Four pharma commerce experts revisit their 2026 predictions on dealmaking, patient access and commercialization at the year's midpoint.

Gifthealth's Chip Parkinson says direct-to-patient adoption has accelerated since January, driven by structural, not cyclical, market forces.

Peli BioThermal and PAXAFE are partnering to pair cold chain packaging with AI-powered monitoring, signaling where pharma logistics technology is headed next.

Gifthealth's Chip Parkinson revisits his 2026 outlook on the direct-to-patient model, and what's developed in H1.

Shortages of antibiotics, IV fluids and sterile injectables are hardening as new EU and US rules push pharma to fix the incentives behind them.

Amy Niles of the Patient Advocate Foundation on the Medicare Part D cap, Medicaid, ACA exchanges and rural hospital access in late 2026.

Geopolitical instability is pushing life sciences firms to map supply chains beyond suppliers to protect trials and patient access.

How commercial trade groups are shifting from distribution execution to strategic partners shaping market access, launch readiness and commercial performance.

Cencora's Brent Wilhelm on how specialty drug growth, cold chain demand, and reimbursement pressure are pushing distributors toward centralized safety stock and AI-driven flexibility.

Amy Niles of the Patient Advocate Foundation on Medicaid work requirements, ACA subsidy expiration and patient affordability in 2026.

In this week's Pharma Pulse, Cardinal Health expands its at-Home Solutions business with two acquisitions, President Trump lays out a phased tariff schedule for generic drugs, and Novo Nordisk sues Eli Lilly over GLP-1 advertising claims.

A subtraction-oriented approach to pharmacy data can surface avoidable drug waste that fragmented systems routinely miss.

Amy Niles of the Patient Advocate Foundation revisits her 2026 outlook on prior authorization reform and the Medicare Prescription Payment Plan.

Novo Nordisk’s complaint argues that Lilly's campaigns leave out information about the most effective injectable doses of Wegovy (semaglutide) and Ozempic (semaglutide), a dispute that could reshape how both companies compete for share in the GLP-1 market.

Ramarketing CEO Emma Banks revisits her "year of two halves" outlook, discussing whether 2026 has followed the same pattern and what she expects for H2.

Doceree launched Semmelweis, an AI model built for pharma commercialization, as drugmakers ramp up AI investment in marketing and sales operations.